Tibotec Pharmaceuticals hopeful for TMC278 after positive Phase III results

摘要

The results from two large-scale clinical trials into the efficacy of TMC278 (provisionally named Rilpivirine; Tibotec Pharmaceuticals, Cork, Ireland), a novel investigational HIV drug, were recently released, showing noninferiority versus efa-virenz in the proportion of patients achieving an undetectable viral load (<50 copies/ml) at week 48.